PPalobiofarma
Palobiofarma is a Spanish clinical-stage biopharmaceutical company founded in 2006 by a group of scientists with drug-discovery experience at pharmaceutical companies such as Bayer, Almirall and Oryzon. It discovers and develops small-molecule drugs based on the modulation of adenosine receptors, with a pipeline spanning oncology, respiratory (COPD/asthma), neurological and rare diseases — including PBF-509 (licensed to Novartis, which triggered milestone payments), PBF-680, PBF-999 for Prader-Willi syndrome and PBF-1129 for non-small-cell lung cancer. Headquartered in Navarra (Noain/Cordovilla, with the AIN building as its more recent site) and with operations in Barcelona, it employs roughly 11-50 people.
SectorsBiotech, Pharmaceuticals, Drug Discovery, Oncology, Rare Diseases
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
Global models 3
A
Arcus Biosciences
United States · arcusbio.com ↗
Clinical-stage biotech that developed small-molecule adenosine-pathway drugs (A2A/A2B antagonists, CD73 inhibitors) for oncology and funded them through pharma partnering deals.
$227MComparable
I
iTeos Therapeutics
Belgium · www.iteostherapeutics.com ↗
Clinical-stage company that developed a small-molecule A2A adenosine receptor antagonist for cancer, funded by VC and pharma licensing.
$180MComparable
CCorvus Pharmaceuticals
United States · www.corvuspharma.com ↗
VC-backed clinical biotech whose lead programme was ciforadenant, an oral A2A adenosine receptor antagonist for cancer immunotherapy.
$114MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 9
Open as list →F
Fitalent
fitalent.com
SSodena
www.sodena.com
IInveready
inveready.com
CCentro para el Desarrollo Tecnológico y la Innovación
www.cdti.es
EEIC Fund
eic.ec.europa.eu
UUnirisco
www.unirisco.com
I
Inveready Biotech II
FFoundation for Prader-Willi Research
G
Genoma España
Funding rounds 3
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-02-12 | No stage disclosed | €7M |
Lead not disclosed
+3 more
|
| 2013-06-19 | Series C (estimated) | €4.5M |
Sodena, Fitalent, Inveready Biotech II
+1 more
|
| 2012-06-15 | Seed (estimated) | €1M |
Lead not disclosed
+3 more
|
News 1
Open as list →| Published | Article |
|---|---|
| 2024-02-02 |
Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor team ↗
Capital-Riesgo.es (English)
2024-02-02 |